High FVIII concentrations interfere with GPVI-mediated platelet activation in vitro

Archive ouverte

Sekar, Rohini | Mimoun, Angelina | Bou-Jaoudeh, Melissa | Loyau, Stéphane | Delignat, Sandrine | Daventure, Victoria | Bonilla, Perrine | Bahle, Aishwarya Sudam | Venkataraman, Krishnan | Rayes, Julie | Boulaftali, Yacine | Jandrot-Perrus, Martine | Proulle, Valérie | Lacroix-Desmazes, Sébastien

Edité par CCSD ; Wiley -

International audience. BackgroundThe recruitment of activated FVIII at the surface of activated platelets is a key step towards the burst of thrombin and fibrin generation during thrombus formation at the site of vascular injury. It involves binding to phosphatidyl-serine (PS) and, possibly, to fibrin bound to αIIbβ3. Seminal work had shown the binding of FVIII to resting platelets, yet without a clear understanding of a putative physiological relevance.ObjectivesTo characterize the FVIII-platelet interaction and its potential modulation on platelet function.MethodsFVIII was incubated with washed platelets. The effects on platelet activation (spontaneously or triggered by collagen and thrombin) were studied by flow cytometry and light transmission aggregometry. We explored the involvement of downstream pathways by studying phosphorylation profiles (western blot). The FVIII-GPVI interaction was investigated by ELISA, confocal microscopy and proximity ligation assay.ResultsFVIII bound to the surface of resting and activated platelets in a dose-dependent manner. FVIII at supra-physiological concentrations did not induce platelet activation but rather specifically inhibit collagen-induced platelet aggregation and altered GPVI-dependent phosphorylation. FVIII rid of its chaperon protein, von Willebrand factor (VWF), interacted in close proximity with GPVI at the platelet surface.ConclusionsWe showed that VWF-free FVIII binding to, or close to, GPVI modulates platelet activation in vitro. This may represent a yet uncharacterized negative feedback loop to control overt platelet activation. Whether local activated FVIII concentrations achieved during platelet accumulation and thrombus formation at the site vascular injury in vivo are compatible with such a function remains to be determined.

Suggestions

Du même auteur

Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab

Archive ouverte | Bou-Jaoudeh, Melissa | CCSD

International audience. Emicizumab is a bispecific chimeric humanized IgG4 that mimics the procoagulant activity offactor VIII (FVIII). Its long half-life and subcutaneous injection route have been life-changingin t...

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice

Archive ouverte | Bou-Jaoudeh, Melissa | CCSD

International audience. Neutralizing anti-factor VIII (FVIII) antibodies, known as FVIII inhibitors, represent a major drawback of replacement therapy in persons with congenital hemophilia A (PwHA), rendering furthe...

Transplacental delivery of therapeutic proteins by engineered IgG: a step towards perinatal replacement therapy

Archive ouverte | Mimoun, Angelina | CCSD

International audience. Background: Transplacental delivery of maternal IgG provides humoral protection during the first months of life until the newborn’s immune system reaches maturity. The materno-fetal interface...

Chargement des enrichissements...